DexCom Company Profile (NASDAQ:DXCM)

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million for the quarter, compared to analysts' expectations of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. DexCom's revenue was up 24.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.24) EPS. View DexCom's Earnings History.

DexCom is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for DexCom.

17 brokers have issued 12-month price targets for DexCom's stock. Their predictions range from $66.00 to $100.00. On average, they anticipate DexCom's share price to reach $86.87 in the next twelve months. View Analyst Ratings for DexCom.

Here are some recent quotes from research analysts about DexCom stock:

• 1. According to Zacks Investment Research, "DexCom reported narrower-than-expected loss in the second quarter. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. In the past one year, DexCom has underperformed the broader industry in terms of price. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash, but also help expand its product portfolio." (8/14/2017)
• 2. Jefferies Group LLC analysts commented, "DXCM reported 4Q sales $3mn ahead of its pre-announcement. Guidance for 2017 remained +25-30% ($710-740mn); importantly, this considers competitive entries by MDT (670G) and ABT (Libre), but does not factor in any contribution from DXCM patients covered by Medicare. With this low bar set for 2017, the next-gen G6 and the Verily Type 2 system coming in 2018, DXCM remains well positioned to succeed in an evolving diabetes landscape. The stock remains a top idea." (3/1/2017)

Some companies that are related to DexCom include Steris Plc (STE), West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), MiMedx Group (MDXG), CONMED Corporation (CNMD), OraSure Technologies (OSUR) and Asante Solutions (PUMP).

DexCom's management team includes the folowing people:

• Terrance H. Gregg, Executive Chairman of the Board
• Kevin R. Sayer, President, Chief Executive Officer, Director
• Kevin M. Sun, Vice President - Finance
• Donald Abbey, Executive Vice President, Quality and Information Technology
• Andrew K. Balo, Executive Vice President - Clinical, Regulatory and Quality
• Richard B. Doubleday, Executive Vice President, Chief Commercial Officer
• Steven R. Pacelli, Executive Vice President - Strategy and Corporate Development
• Heather Ace, Senior Vice President, Human Resources
• Jake Leach, Senior Vice President of Research and Development
• Jeffrey C. Moy, Senior Vice President - Operations

DexCom's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (12.50%), Janus Henderson Group PLC (7.89%), Vanguard Group Inc. (7.88%), Baillie Gifford & Co. (7.04%), Artisan Partners Limited Partnership (6.56%) and BlackRock Inc. (5.07%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

DexCom's stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Gilder Gagnon Howe & Co. LLC, Frontier Capital Management Co. LLC, Baillie Gifford & Co., Lord Abbett & CO. LLC, Bamco Inc. NY, Alliancebernstein L.P. and Wells Fargo & Company MN. Company insiders that have sold DexCom stock in the last year include Andrew K Balo, Jacob Steven Leach, Jay S Skyler, Jess Roper, John Lister, Jorge A Valdes, Kevin R Sayer, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for DexCom.

DexCom's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Winslow Capital Management LLC, FMR LLC, Bank of New York Mellon Corp, Fred Alger Management Inc., Ameriprise Financial Inc., Goldman Sachs Group Inc. and AXA. View Insider Buying and Selling for DexCom.

Shares of DexCom can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DexCom stock can currently be purchased for approximately $70.23.